fda bpc-157 not approved human use warning unapproved peptide safety risks new drug The FDA has issued clear signals FDA panel backs easier access

Monitoring and adjusting based on results Weight loss peptide protocols require ongoing assessment and potential adjustment

No validated dosing, pharmacokinetics, or long-term safety There is no human pharmacokinetic data for injectable BPC-157: How long it lasts in the body What tissues it reaches Whether it accumulates How it is metabolized or excreted Long-term risks cannot be assessed without such information

The compound is relatively stable but should be aliquoted upon reconstitution to minimize freeze-thaw cycles in solution

Bacteriostatic water contains a preservative (typically benzyl alcohol) that prevents bacterial growth